FDA approves Luxturna to treat patients with inherited retinal disease

21 December 2017
Source: FIght for Sight

The US Food and Drug Administration (FDA) has this week approved the first ever gene therapy treatment, Luxturna (Voretigene Neparvovec), for inherited retinal diseases (IRD).The gene therapy drug will be used as a treatment for patients with vision loss caused by RPE65 gene mutations. Mutations in the RPE65 gene are associated with two main types of IRDs – retinitis pigmentosa

Read more FDA approves Luxturna to treat patients with inherited retinal disease